Skip to content

The Role of Genetic Factors in the Development of Idiopathic Osteoarthritis of the Knee in the Kazakh Population

Preventive and Personalized Medicine (2021-2023)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05095142
Enrollment
500
Registered
2021-10-27
Start date
2022-03-30
Completion date
2023-01-20
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Osteoarthritis

Keywords

SNP

Brief summary

The purpose of this study is to identify genetic determinants of susceptibility to idiopathic osteoarthritis of the knee . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of idiopathic osteoarthritis of the knee

Interventions

SNP analysis of the DNA obtained from peripheral blood sample

Sponsors

Asfendiyarov Kazakh National Medical University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 68 Years

Inclusion criteria

1. Patients with bilateral idiopathic gonarthrosis aged 18 to 65 years; 2. Representatives of the Kazakh ethnic group up to the 3rd generation; 3. Hereditary history of arthrosis; 4. Persons who are able and willing to provide written informed consent;

Exclusion criteria

1. Patients with bilateral idiopathic gonarthrosis under 18 years of age and over 65 years of age; 2. Representatives of other ethnic groups; 3. Representatives of the Kazakh ethnic group less than 3 generations; 4. No family history of bilateral idiopathic gonarthrosis; 5. Patients with an acute period of the inflammatory process (laboratory and clinical signs); 6. Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; 7. Pregnant or lactating women; 8. Tuberculosis of any localization in the active phase and in history; 9. Severe and decompensated diseases of the liver and kidneys, cardiovascular system; 10. Severe and decompensated course of endocrine diseases; 11. Autoimmune diseases; 12. Systemic diseases; 13. Oncological diseases;

Design outcomes

Primary

MeasureTime frameDescription
enotyping for the SNP associated with liver cirrhosis1 yearGenotype frequency of SNP in the study genes of participants and control participants.

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026